Table 7.
Univariate and multivariate logistic regression analysis of risk factors for presence of vision-threatening adverse events
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P value | OR | 95%CI | P value | |
| Age | 0.974 | 0.926–1.024 | 0.297 | - | - | - |
| Gender | 1.892 | 0.461–7.767 | 0.376 | - | - | - |
| BMI | 1.212 | 0.999–1.471 | 0.052 | - | - | - |
| Diabetes type | - | - | 0.999 | - | - | - |
| Duration of diabetes | 0.880 | 0.788–0.984 | 0.025* | 0.905 | 0.794–1.032 | 0.137 |
| Family history of diabetes | 0.181 | 0.022–1.522 | 0.116 | - | - | - |
| MAP | 0.992 | 0.953–1.032 | 0.677 | - | - | - |
| HbA1c | 1.048 | 0.707–1.555 | 0.814 | - | - | - |
| TC | 1.381 | 0.871–2.192 | 0.17 | - | - | - |
| HDL | 0.458 | 0.064–3.272 | 0.437 | - | - | - |
| LDL | 1.62 | 0.883–2.971 | 0.119 | - | - | - |
| TG | 1.113 | 0.618–2.003 | 0.721 | - | - | - |
| ALT | 1.011 | 0.963–1.062 | 0.657 | - | - | - |
| AST | 1.008 | 0.931–1.092 | 0.836 | - | - | - |
| ALP | 1.004 | 0.984–1.023 | 0.724 | - | - | - |
| GFR | 0.996 | 0.979–1.013 | 0.633 | - | - | - |
| DRSS levels at baseline | 3.868 | 1.847–8.102 | < 0.001*** | 3.668 | 1.710–7.868 | 0.001** |
| Presence of DME at baseline | 0.316 | 0.087–1.140 | 0.078 | - | - | - |
| Numbers of conbercept injections | 0.837 | 0.609–1.151 | 0.274 | - | - | - |
| The interval between PRP and IVC | 0.532 | 0.155–1.828 | 0.317 | - | - | - |
OR odds ratio, CI confidence interval, BMI body mass index, MAP mean arterial pressure, HbA1c glycated hemoglobin, TC total cholesterol, HDL high density lipoprotein, LDL low density lipoprotein, TG triglyceride, ALT glutamic pyruvic transaminase, AST glutamic oxaloacetic transaminase, ALP alkaline phosphatase, GFR glomerular filtration rate, DRSS diabetic retinopathy severity scale, DME diabetic macular edema, PRP panretinal photocoagulation, IVC intravitreal conbercept
* P < 0.05, ** P < 0.01, *** P < 0.001